China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

Equities

000999

CNE0000011K8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 14/07/2024 BST 5-day change 1st Jan Change
41.9 CNY +1.92% Intraday chart for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. +0.48% +9.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Resources Sanjiu Medical & Pharmaceutical Signs 90-Million-Yuan Energy Supply Renewal Deal MT
CR Sanjiu Medical and Pharmaceutical to Sell 51% of China Resources Shenghuo for 1.79 Billion Yuan MT
KPC Pharmaceuticals,Inc agreed to acquire 51% stake in China Resources Kunming Shenghuo Pharmaceutical Co., Ltd. from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for CNY 1.8 billion. CI
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024 CI
CR Sanjiu Ties Up With China Resources Power on New Energy Projects MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CR Sanjiu's 2023 Profit Climbs 16.5%, Revenue Jumps 37% MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend CI
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Resources Sanjiu Sees Up to 32% Jump in 2023 Profit MT
CR Sanjiu Expects Increase in 2023 Profit MT
Chongqing Changsheng Shenghe Pharmaceutical Private Equity Investment Fund Partnership Enterprise and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. agreed to acquire 18.7751% stake in Runsheng Pharmaceutical Co., Ltd. from Chongqing Boyi Xintian Equity Investment Fund Partnership Enterprise (Limited Partnership), Tasly Capital and Chongqing Juxin Investment Co., Ltd. for CNY 58.9 million . CI
Respirent Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 127.97619 million in funding from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Chongqing Changsheng Shenghe Pharmaceutical Private Equity Investment Fund Partnership Enterprise CI
China Resources Power Unit to Provide Financial Assistance to Affiliate MT
CR Sanjiu Medical & Pharmaceutical Unit's Hypertension Drug Chosen for China's Centralized Procurement MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China Resources Sanjiu to Invest Up to 3.5 Billion Yuan in Bank Financial Products MT
CR Sanjiu Medical & Pharmaceutical's H1 Attributable Profit Rises 31% MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
CR Sanjiu Medical’s Analgesic Tablet Shortlisted For China’s Drug Procurement Program MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 15 June 2023 CI
China Resources Sanjiu Medical & Pharmaceutical's Q1 Net Profit Surges MT
China Resources Power to Cooperate on New Energy Projects with China Resources Sanjiu Medical MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Enters into the Cooperation Agreement with China Resources Power Holdings Company Limited CI
Chart China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
More charts
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily prescribed drugs, OTC drugs and generic drugs.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
41.9 CNY
Average target price
55.23 CNY
Spread / Average Target
+31.81%
Consensus
  1. Stock Market
  2. Equities
  3. 000999 Stock
  4. News China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  5. CR Sanjiu Medical & Pharma to Buy 28% Stake in KPC Pharma For $430 Million